NeuroMetrix (NURO) Competitors

NeuroMetrix (NASDAQ:NURO) and Outset Medical (NASDAQ:OM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, community ranking, dividends, earnings, profitability and institutional ownership.

Do analysts recommend NURO or OM?

Outset Medical has a consensus target price of $57.00, suggesting a potential upside of 385.73%. Given Outset Medical's stronger consensus rating and higher probable upside, analysts clearly believe Outset Medical is more favorable than NeuroMetrix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroMetrix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Outset Medical	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Does the MarketBeat Community believe in NURO or OM?

NeuroMetrix received 260 more outperform votes than Outset Medical when rated by MarketBeat users. Likewise, 56.91% of users gave NeuroMetrix an outperform vote while only 38.10% of users gave Outset Medical an outperform vote.

Company	Underperform	Outperform
NeuroMetrix	Outperform Votes 284 56.91%	Underperform Votes 215 43.09%
Outset Medical	Outperform Votes 24 38.10%	Underperform Votes 39 61.90%

Does the media favor NURO or OM?

In the previous week, NeuroMetrix and NeuroMetrix both had 4 articles in the media. Outset Medical's average media sentiment score of 1.02 beat NeuroMetrix's score of 0.72 indicating that Outset Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroMetrix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Outset Medical	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, NURO or OM?

NeuroMetrix has a beta of 2.15, suggesting that its stock price is 115% more volatile than the S&P 500. Comparatively, Outset Medical has a beta of 2.01, suggesting that its stock price is 101% more volatile than the S&P 500.

Do institutionals and insiders hold more shares of NURO or OM?

19.4% of NeuroMetrix shares are held by institutional investors. 7.3% of NeuroMetrix shares are held by insiders. Comparatively, 4.1% of Outset Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Is NURO or OM more profitable?

Outset Medical has a net margin of -112.57% compared to NeuroMetrix's net margin of -203.71%. NeuroMetrix's return on equity of -42.56% beat Outset Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroMetrix	-203.71%	-42.56%	-39.26%
Outset Medical	-112.57%	-175.64%	-38.61%

Which has stronger valuation and earnings, NURO or OM?

NeuroMetrix has higher earnings, but lower revenue than Outset Medical. NeuroMetrix is trading at a lower price-to-earnings ratio than Outset Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroMetrix	$3.77M	2.45	-$6.53M	-$4.59	-0.98
Outset Medical	$113.69M	0.37	-$172.80M	-$37.18	-0.32

Summary

NeuroMetrix beats Outset Medical on 10 of the 17 factors compared between the two stocks.